drugset / Trial / NCT02676310
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
Timeline
- Start
- 2016-03
- Primary completion
- 2017-01
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimatoprost | Other / unclassified | 0.25 ml | Topical |
| Subject | Bimatoprost | Other / unclassified | 0.3 % | Topical |
| Subject | Bimatoprost | Other / unclassified | 1 % | Topical |
| Subject | Bimatoprost | Other / unclassified | 1 ml | Topical |
| Subject | Bimatoprost | Other / unclassified | 3 % | Topical |